and expedite the review of new therapies intended to treat serious conditions and fill an unmet need. Fallbacks include frequent communication with the FDA regarding the drug’s development.

Breakthrough Therapy: This designation is for therapies that have preliminary clinical evidence indicating a substantial improvement over existing therapies. Benefits include all the Fast Track features, plus intensified guidance from the FDA.

Priority Review: This designation shortens the review time of applications, typically from 10 months to 6 months, for drugs that offer significant advances in treatment or provide a treatment where none exist.

Accelerated Approval: This program allows drugs to be approved based on surrogate endpoints that are reasonably likely to predict clinical benefit, thus expediting their availability to patients.

These programs can significantly impact development timelines and provide a path to obtaining necessary approvals while ensuring patient safety and therapeutic efficacy.

Step 1: Identify Unmet Medical Needs

The first step in designing a development program geared towards qualifying for an expedited review is to identify an unmet medical need. This recognition should involve systematic evaluation through several lenses:

• Market Analysis: Determine gaps in current therapies and assess the existing treatment landscape. The analysis should include patient populations that experience significant morbidity or mortality from a disease with limited or no available treatment options.
• Clinical Evidence: Gather data from literature, clinical trials, and real-world evidence to substantiate that the product being developed addresses a genuine unmet need and presents substantial benefits over existing therapies.
• Consult Stakeholders: Engaging with healthcare professionals, patients, and regulatory bodies can provide insights and validate perceptions of unmet medical needs within specific therapeutic areas.

Once a clear unmet need has been established, the next step entails developing the drug in alignment with the identified needs.

Step 2: Strategy Designing Following FDA Guidance

After identifying the unmet need, it is crucial to develop a strategic plan following the relevant FDA guidance documents. Knowledge of the appropriate regulations under 21 CFR is integral to ensuring compliance. Key considerations should include:

• Pre-IND Meetings: Request a pre-Investigational New Drug (IND) application meeting with the FDA. This strategy will provide an opportunity to discuss your development program and seek clarity on the data requirements and regulatory expectations for your product.
• Development Plans: Design your clinical development program with clear endpoints, including surrogate endpoint definitions for Accelerated Approval, if applicable. Make sure these endpoints are aligned with available FDA guidance.
• Review of Breakthrough Designation Criteria: If your drug demonstrates substantial improvement over existing options, consider applying for Breakthrough Therapy designation to benefit from intensive guidance and expedited review.

In conclusion of this step, ensure that all development decisions are documented and substantiated with evidence to facilitate the regulatory review process.

Step 3: Engagement with the FDA Throughout Development

Maintaining consistent engagement with the FDA during the development process is critical for navigating regulatory requirements. This includes:

• Regular Updates: Provide the FDA with regular updates on development progress and issues arising within the clinical development program. A pro-active approach will help build rapport and foster a collaborative relationship.
• Safety Monitoring: Implement robust safety and adverse event monitoring protocols. Use this data to support ongoing development and, where necessary, modify clinical trial protocols to ensure participant safety.
• Expanded Access Programs: In cases where the product shows promise, consider establishing expanded access mechanisms to provide support to patients in need of therapy while still undergoing clinical development.

Active communication ensures that any potential feedback from the FDA is addressed immediately, avoiding delays later in the review process.

Step 4: Submit Application for Expedited Designation

Once the necessary data has been collected, the next step is to submit an application for expedited designation. The application process varies by designation type:

• Fast Track: Submit a Fast Track request during the submission of your IND application or a New Drug Application (NDA). Justify the request by clearly explaining how the drug addresses an unmet medical need.
• Breakthrough Therapy: A Breakthrough Therapy designation request requires similar documentation but must provide robust preliminary clinical evidence for the substantial improvement over existing treatments.
• Priority Review: Priority Review designation is requested within the NDA/BLA submission, emphasizing the significance of the therapeutic advance.
• Accelerated Approval: Ensure that the requested approval is supported with appropriate surrogate endpoints and plan for post-marketing confirmatory trials to validate therapeutic effects.

Review the FDA guidance documents related to each designation for specific requirements and ensure all the necessary supporting data is included to facilitate timely review.

Step 5: Clinical Trial Design Considerations

The design of clinical trials is crucial for maximizing the chances of qualifying for expedited programs. Key considerations include:

• Use of Surrogate Endpoints: For Accelerated Approval, utilize surrogate endpoints that are likely to predict clinical benefit. Review established precedents, such as oncology case studies where surrogate results were accepted for accelerated pathways.
• Confirmatory Trials: When applying for Accelerated Approval, plan for confirmatory trials post-approval to verify sustained clinical benefit as required by the FDA, which can enhance the likelihood of long-term approval.
• Statistical Design: Ensure the trial design is statistically sound with clear hypotheses, sample sizes, and analyses plans validated by prior meetings with the FDA.

Optimal trial design not only supports regulatory submission but also facilitates informed decision-making by stakeholders and patients regarding the benefits and risks of the therapy.

Step 6: Post-Approval Requirements and REMS

Once approval is obtained through any of the expedited programs, it is crucial to understand and comply with post-approval requirements, including the Risk Evaluation and Mitigation Strategy (REMS) when necessary. Key steps include:

• Understanding REMS: In cases where there is a need to mitigate risks associated with a drug, implement a REMS. This may include risk communication strategies, restricted distribution plans, or additional monitoring requirements.
• Regular Reporting: Adhere to ongoing reporting requirements, including safety reporting on adverse events, effectiveness assessments, and outcomes from confirmatory trials.
• Engagement with FDA in Post-Marketing Studies: Ensure continual collaboration with the FDA while conducting post-marketing studies, modifications to labeling, or new indication requests to maintain compliance and streamline future submissions.

These steps prevent regulatory violations and ensure continued access to therapies for patients while providing the FDA with necessary data to inform future decisions regarding the drug.

Conclusion: Implementing a Comprehensive Strategy

Designing a development program to qualify for FDA expedited review requires strategic planning, proactive communication with FDA, adherence to regulatory guidelines, and an understanding of the needs of the patient population. It also involves integrating clinical evidence and stakeholder insights to align development goals with patient needs and regulatory requirements.

As a final note, companies should remain vigilant about ongoing changes in both US and international regulations, such as the emerging frameworks from the EMA under the PRIME scheme and standards of conditional approval, ensuring continued alignment with international best practices while pursuing expedited programs.